



**Coordination**

○ Christian JORGENSEN      Montpellier      *christian.jorgensen@inserm.fr*

**Project management**

○ Séverine KREMER      Montpellier      *severine.kremer@umontpellier.fr*

**GMP Production of ATMPs**

○ Hélène ROUARD      Créteil      *helene.rouard@efs.sante.fr*  
 ○ Sandrine FLEURY      Toulouse      *sandrine.fleury@efs.sante.fr*  
 ○ Anaïck MOISAN      Grenoble      *anaick.moisan@efs.sante.fr*  
 ○ Fabienne POUTHIER      Besançon      *fabienne.pouthier@efs.sante.fr*  
 ○ Christophe MARTINAUD      Clamart      *martinaudctsa@gmail.com*

**Safety controls and potency assays**

○ Louis CASTEILLA      Toulouse      *louis.casteilla@inserm.fr*

**Immunomonitoring**

○ Karin TARTE      Rennes      *karin.tarte@univ-rennes1.fr*  
 ○ Pascale LOUIS-PLENCE      Montpellier      *pascale.plence@inserm.fr*

**Preclinical studies: MSC safety and efficacy in animal models**

○ Danièle NOEL      Montpellier      *daniele.noel@inserm.fr*

**Clinical trial design and support**

○ Christian JORGENSEN      Montpellier      *christian.jorgensen@inserm.fr*



**NATIONAL NETWORK FOR REGENERATIVE MEDICINE**

The **ECELLFrance** infrastructure coordinates the key players in the innovative field of mesenchymal stem cell (MSC)-based therapies

**ECELLFrance** federates:

- ❖ Advanced Therapy Medicinal Products (ATMP) production platforms
- ❖ research teams with expertise on translational research in cell therapy
- ❖ clinical research teams to cover phase I and II clinical studies




The **ECELLFrance** infrastructure is an integrated network ensuring a high level of expertise in the production and development of MSC-based medicinal products for the treatment of major medical indications.

**ECELLFrance** offers to assist both academic and industrial partners with the implementation of their pre-clinical and/or clinical programs in the emerging field of cell-based therapies

**ECELLFrance** services cover

the entire MSC-based production and development pipeline:

- GMP production of ATMPs in accordance with EC regulation n°1394/2007
- Safety and potency tests for ATMPs
- Immunomonitoring of MSC-treated patients
- Pre-clinical development of MSC-based medicinal products
  - Evaluation of MSC-based therapies in a wide range of animal models
    - Osteoarticular diseases
    - Autoimmune diseases
    - Lower limb ischemia
    - Myocardial ischemia
    - Ischemic cerebrovascular diseases
    - Thermal or radio-induced cutaneous burns
  - Non-clinical safety studies
    - Biodistribution
    - Pharmacotoxicology
- Regulatory support services
- Clinical trial support services for phase I and phase II trials



**Coo** Coordination/Headquarters  
**Prod** MSC production  
**QC** QC, potency  
**Pre-C** Preclinical studies  
**Imm** Immunomonitoring

